The global pediatric neuroblastoma treatment market is anticipated to grow at a CAGR of 10.3% during the forecast period. Product approvals and clinical trials have paved the way for the introduction of new therapeutic options, addressing the complex nature of neuroblastoma and improving treatment outcomes. Through the process of product approvals, regulatory authorities such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) evaluate the data generated from clinical trials and approve the marketing and distribution of promising pediatric neuroblastoma treatments. For instance, in October 2022, Kyushu University sponsored a clinical trial under the title “Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas or Malignant Pediatric Solid Tumors With Lung Metastases” to evaluate the safety of GAIA-102 alone refractory/relapse neuroblastoma or pediatric solid tumors with lung metastases and to decide a recommended dose for Phase II. In February 2022, the U.S. FDA granted a Fast Track Designation (FTD) to the targeted inhibitor alrizomadlin (APG-115) for the treatment of neuroblastoma as a rare pediatric disease (RPD).In June 2021, Y-mAbs Therapeutics, Inc. a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of neuroblastoma cancer. The FDA-approved product DANYELZA is launched by the company which will benefit neuroblastoma patients.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/pediatric-neuroblastoma-treatment-market
R&D activities are key trend gaining popularity in the pediatric neuroblastoma treatment market. Major companies operating in the pediatric neuroblastoma treatment market are focusing on advanced research and development to sustain their position in the market. For instance, in July 2020, Clarity Pharmaceuticals, an Australia-based radiopharmaceutical company, announced that the 67Cu-SARTATETM trial for pediatric patients with neuroblastoma has begun at Memorial Sloan Kettering Cancer Center (MSK) in New York City. The 67Cu-SARTATETM trial is a Peptide Receptor Radionuclide Therapy (PRRT) trial for children with high-risk neuroblastoma. MSK is conducting a multi-center, dose-escalation, open-label, non-randomized Phase 1/2a theranostic clinical investigation.
Market Coverage
- The market number available for – 2022-2030
- Base year- 2022
- Forecast period- 2023-2030
- Segment Covered-
o By Treatment Type
o By End-User
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- including APEIRON Biologics AG, Baxter Healthcare Corp., Cellectar Biosciences, Inc., and United Therapeutics Corp. among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Pediatric Neuroblastoma Treatment Market Report Segment
By Treatment Type
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Others (Surgery, Targeted Therapy)
By End-User
- Hospitals
- Specialty Clinics
- Others (Research Institutes)
A full report of Pediatric Neuroblastoma Treatment Market available @ https://www.omrglobal.com/industry-reports/pediatric-neuroblastoma-treatment-market
Pediatric Neuroblastoma Treatment Market Report Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- AstraZeneca
- Bayer AG
- Bristol-Myers Squibb Co.
- Cell Ectar Biosciences Inc.
- Clarity Pharmaceuticals
- Eli Lilly and Company
- Hoffmann-La Roche AG
- Johnson & Johnson Services, Inc.
- MacroGenics Inc.
- Marsala Biotech Inc.
- Merck & Co.
- Pfizer Inc.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
